Antiretroviral therapy (ART) has transformed HIV from a fatal diagnosis into a manageable chronic condition. Today, more than 30 individual antiretroviral drugs across nine mechanistic classes are FDA-approved — offering clinicians and patients a range of options suited to different resistance profiles, tolerability needs, and lifestyle preferences.
This guide covers all nine FDA-recognized HIV drug classes, the DHHS-recommended first-line regimens for 2026, long-acting injectable options, PrEP, and what these medications typically cost. If you have questions about your specific regimen, your HIV specialist is the right source of guidance.
- 30+ individual drugs are FDA-approved across nine classes
- INSTI-based regimens are the cornerstone of modern first-line treatment
- Single-tablet regimens (STRs) allow most patients to take one pill once daily
- Long-acting injectables (monthly, bimonthly, or twice-yearly) now offer pill-free alternatives
- U=U is confirmed: undetectable viral load means HIV cannot be sexually transmitted
- No cure exists, but ART taken consistently gives near-normal life expectancy
The Nine Classes of HIV Medications
HIV medications work by blocking different steps in the HIV replication cycle. Combination therapy — using drugs from two or more classes — prevents the virus from developing resistance to any single mechanism.
Classes 5 through 9 (fusion inhibitors, CCR5 antagonists, CD4 post-attachment inhibitors, gp120 attachment inhibitors, and capsid inhibitors) are generally reserved for patients with multi-drug resistant HIV or those who have exhausted other options. Most treatment-naive patients start with an INSTI + two NRTIs.
DHHS-Recommended First-Line Regimens (2026)
The U.S. Department of Health and Human Services (DHHS guidelines) recommend INSTI-based regimens for most treatment-naive adults. All preferred options below are once-daily, single-tablet regimens.
| Regimen | Components | Key Notes |
|---|---|---|
| Biktarvy | Bictegravir / emtricitabine / TAF | Most prescribed HIV regimen in the US. High barrier to resistance. Once daily. |
| Triumeq | Dolutegravir / abacavir / lamivudine | Requires HLA-B*5701 testing before use (abacavir hypersensitivity risk). Once daily. |
| Dovato | Dolutegravir / lamivudine (2-drug) | First preferred 2-drug regimen. Not for patients with HBV co-infection or resistance concerns. Once daily. |
| Cabenuva | Cabotegravir / rilpivirine (injectable) | For virologically suppressed patients. Given monthly or every 2 months by injection. No daily pill required. |
Regimen selection is highly individualized. Your clinician will consider your resistance profile, HLA-B*5701 status, kidney and bone health, co-infections (particularly hepatitis B), other medications, and personal preferences before selecting a regimen. Never switch or stop ART without medical guidance.
Long-Acting Injectable HIV Medications
Long-acting injectables eliminate the need for daily pills, replacing them with periodic clinic visits for injections. They are now an established option for both HIV treatment and prevention (PrEP).
For HIV Treatment
- Cabenuva (cabotegravir + rilpivirine): Given monthly or every two months by intramuscular injection. Approved for adults who are virologically suppressed on a stable oral regimen. The first complete injectable ART regimen.
- Sunlenca (lenacapavir): Given by subcutaneous injection every six months, combined with an oral background regimen. Approved for adults with multi-drug resistant HIV who have limited treatment options.
For PrEP (HIV Prevention)
- Apretude (cabotegravir): Given every two months by intramuscular injection. Approved for HIV-negative adults and adolescents at risk. Shown to be more effective than daily oral Truvada in clinical trials.
- Yeztugo (lenacapavir): Given every six months. The first twice-yearly PrEP option, approved in 2025. Demonstrated over 99% efficacy in the PURPOSE 1 and PURPOSE 2 trials.
Twice-yearly PrEP is now available. Yeztugo (lenacapavir) was approved in 2025 — two injections per year provide continuous HIV prevention. This option may be particularly beneficial for patients who struggle with daily pill adherence.
PrEP Options in 2026
Pre-Exposure Prophylaxis (PrEP) is for HIV-negative individuals at risk of HIV. It is distinct from HIV treatment: PrEP prevents infection; ART treats it. Current FDA-approved PrEP options include:
| Drug | Dosing | Route | Notes |
|---|---|---|---|
| Truvada (TDF/FTC) | Daily | Oral | Original approved PrEP. Generic available. |
| Descovy (TAF/FTC) | Daily | Oral | Not approved for receptive vaginal sex. Better kidney/bone profile than TDF. |
| Apretude (cabotegravir) | Every 2 months | Injection | Higher efficacy than daily oral in trials. Requires clinic visits. |
| Yeztugo (lenacapavir) | Every 6 months | Injection | Twice-yearly. >99% efficacy in PURPOSE trials. Approved 2025. |
Side Effects of HIV Medications
Modern INSTI-based regimens are generally well tolerated, particularly compared to older regimens. Most patients starting Biktarvy or dolutegravir-based therapy experience few significant side effects.
Common Early Side Effects
- Nausea, headache, and fatigue — often resolve within the first 2–4 weeks
- Insomnia or vivid dreams, particularly with dolutegravir-based regimens
- Diarrhea or loose stools, usually mild and transient
Longer-Term Monitoring Points
- Weight gain: Associated with newer INSTI + TAF combinations, particularly dolutegravir and bictegravir. Mechanisms are not fully understood.
- Kidney function: TDF-based regimens require monitoring; TAF has a better renal safety profile.
- Bone density: TDF is associated with modest reductions in bone mineral density. TAF and INSTI-based regimens have lower impact.
- Metabolic markers: Lipid profiles and blood glucose should be monitored periodically.
Do not stop ART because of side effects without speaking to your clinician first. Many side effects are manageable or resolve on their own. Stopping treatment can lead to viral rebound and immune decline. If a side effect is affecting your quality of life, there are usually alternative regimens available.
How Much Do HIV Medications Cost?
HIV drug list prices in the US are among the highest in the world. However, most patients do not pay the list price. The key cost pathways are:
- Commercial insurance + manufacturer copay card: Most commercially insured patients pay $0–$5/month with Gilead’s or ViiV’s copay assistance programs.
- Medicare Part D + Extra Help: Patients with Low-Income Subsidy (Extra Help) typically pay $4–$9/month. Manufacturer copay cards cannot be used with Medicare.
- Medicaid: HIV medications are covered in all state Medicaid programs, usually with minimal or no copay.
- Ryan White / ADAP: The AIDS Drug Assistance Program provides free or low-cost HIV medications to uninsured and underinsured patients. Find your state program at nastad.org/adap-watch.
- Manufacturer patient assistance programs: Gilead and ViiV offer free medication to qualifying uninsured patients. Call Gilead Advancing Access at 1-800-226-2056.
- 340B pricing: Ryan White clinics and federally qualified health centers may offer lower medication costs through the 340B program. Ask your clinic if they participate.
Never stop ART because of cost concerns without speaking to your clinician or clinic social worker. Emergency fill programs and assistance pathways can often be arranged within days. Contact your prescriber and ask about the Ryan White program, ADAP, or manufacturer assistance immediately.
Undetectable = Untransmittable (U=U)
U=U is one of the most important advances in HIV science. People living with HIV who maintain an undetectable viral load through consistent ART have effectively zero risk of sexually transmitting HIV to a partner.
This conclusion is supported by landmark clinical studies including HPTN 052, the PARTNER and PARTNER2 studies, and Opposites Attract — collectively observing zero transmissions among couples where the HIV-positive partner had an undetectable viral load. U=U is endorsed by the NIH, CDC, UNAIDS, and more than 1,100 organizations in 105 countries.
Achieving and maintaining an undetectable viral load requires consistent adherence to ART. Regular viral load monitoring — typically every 3–6 months — confirms suppression.
New HIV Medications: 2026–2027 Pipeline
HIV drug development continues to advance toward longer-acting options, improved resistance coverage, and new mechanisms.
- Bictegravir / lenacapavir single-tablet regimen (Gilead): Based on positive ARTISTRY-1 and ARTISTRY-2 trial results, Gilead has submitted for FDA approval. A potential 2027 launch would combine a high-barrier INSTI with a capsid inhibitor in one daily tablet — offering strong activity against INSTI-resistant virus.
- VH-184 (ViiV Healthcare): A third-generation INSTI with activity against dolutegravir- and bictegravir-resistant HIV. Phase 1 data support long-acting injectable formulation development.
- Islatravir / MK-8507 (Merck): Islatravir is a novel nucleoside reverse transcriptase translocation inhibitor (NRTTI) with a distinct mechanism from existing NRTIs. Development is ongoing following earlier dose-finding work.
- Broadly neutralizing antibodies (bNAbs): Bispecific and trispecific bNAb combinations are in clinical trials as both treatment and prevention strategies.
- Weekly oral options: Several investigational candidates aim to reduce dosing to once weekly, bridging the gap between daily oral therapy and long-acting injectables.
Frequently Asked Questions
The DHHS guidelines recommend INSTI-based regimens for most people starting treatment. Preferred options include Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide), Triumeq (dolutegravir/abacavir/lamivudine) for HLA-B*5701 negative patients, and Dovato (dolutegravir/lamivudine) for certain patients. All three are single-tablet, once-daily regimens. Cabenuva is recommended for virologically suppressed patients who prefer injectable treatment.
There are nine FDA-recognized classes: NRTIs, NNRTIs, INSTIs, protease inhibitors, fusion inhibitors, CCR5 antagonists, CD4 post-attachment inhibitors (ibalizumab/Trogarzo), gp120 attachment inhibitors (fostemsavir/Rukobia), and capsid inhibitors (lenacapavir). Most treatment regimens combine drugs from two or three classes.
HIV treatment (ART) is for people living with HIV — it suppresses the virus to undetectable levels. PrEP is for HIV-negative people at risk — it prevents infection. Treatment uses multiple drugs; PrEP uses one or two. Both are highly effective when used as directed. Current PrEP options include daily oral pills (Truvada, Descovy) and long-acting injectables (Apretude every two months, Yeztugo every six months).
Long-acting injectables replace daily pills with periodic injections. Cabenuva is given every one or two months for treatment. Apretude is given every two months for PrEP. Yeztugo (lenacapavir) is given twice yearly for PrEP, and Sunlenca (lenacapavir) is used every six months for treatment of drug-resistant HIV.
There is currently no cure for HIV. However, ART can suppress the virus to undetectable levels, meaning it cannot be sexually transmitted (U=U) and the immune system can recover. ART must be taken consistently for life to maintain suppression. Researchers are investigating functional cures including broadly neutralizing antibodies and gene therapies.
List prices range from about $60/month (generic Truvada) to over $4,500/month (Cabenuva) depending on the regimen. However, most patients pay far less through insurance, manufacturer copay cards, ADAP, 340B, or patient assistance programs. Many patients pay $0 with available assistance. In January 2026, CMS selected Biktarvy for Medicare price negotiations, with a negotiated price effective in 2028.
Modern INSTI-based regimens are generally well tolerated. Common early side effects may include nausea, headache, and fatigue, which often resolve within weeks. Weight gain has been associated with newer regimens, particularly those combining dolutegravir or bictegravir with TAF. Your clinician will monitor for specific concerns including kidney function, bone density, weight, and metabolic markers.
Take the missed dose as soon as you remember, unless it’s close to your next dose. Don’t double up. Occasional missed doses are unlikely to cause immediate harm, but consistent adherence prevents drug resistance. If you frequently miss doses, discuss strategies or long-acting injectable options with your clinician.
U=U means people with HIV who maintain an undetectable viral load through ART have effectively no risk of sexually transmitting HIV. This is confirmed by multiple large studies (HPTN 052, PARTNER/PARTNER2, Opposites Attract) and endorsed by the NIH, CDC, UNAIDS, and over 1,100 organizations in 105 countries.
Yes. Gilead is seeking approval for a bictegravir/lenacapavir single-tablet regimen based on positive ARTISTRY trial results, with a potential 2027 launch. ViiV Healthcare’s VH-184, a third-generation INSTI with activity against resistant HIV, has Phase 1 data supporting long-acting formulation. Merck’s islatravir (a novel NRTTI) is in development. Researchers are also studying broadly neutralizing antibodies and weekly oral options.
How we reviewed this article:
Sunny Pharma follows strict sourcing guidelines and relies on peer-reviewed studies, government agencies (FDA, NIH, CDC, WHO), academic research institutions, and medical associations (DHHS, IDSA). We use only credible, verifiable sources to ensure accuracy. Learn more in our editorial policy.
Sources & References
- DHHS Guidelines for Antiretroviral Agents in Adults and Adolescents with HIV: clinicalinfo.hiv.gov
- NIH — FDA-Approved HIV Medicines: hivinfo.nih.gov
- WHO — Updated Recommendations on HIV Clinical Management (2026): who.int
- CDC — HIV Guidelines and Recommendations: cdc.gov
- FDA — Biktarvy Prescribing Information (2025): accessdata.fda.gov
- PARTNER2 Study — The Lancet: thelancet.com
- HPTN 052 — NEJM: nejm.org
- Gilead PURPOSE 1 & 2 trials — lenacapavir for PrEP: gilead.com
- NASTAD ADAP Watch: nastad.org
- HRSA — Ryan White HIV/AIDS Program: ryanwhite.hrsa.gov
- HRSA — Find HIV Care Locator: findhivcare.hrsa.gov
- CMS — Biktarvy Selected for Medicare Negotiation (Jan 2026): positivelyaware.com